GENMAB A/S (GMAB) Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Genmab A/S NASDAQ:GMAB Healthcare · Biotechnology
Mkt Cap $35.09B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Critical
Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab's Phase 3 LiGeR-HN1 trial met both co-primary endpoints at the first interim analysis, with petosemtamab plus pembrolizumab cutting the risk of death by 50% (OS HR 0.50, p<0.0001) in first-line PD-L1+ recurrent/metastatic head and neck cancer.
Objective response rate also improved significantly (odds ratio 3.17, p<0.0001), regardless of HPV status, and no new safety signals were identified.
Genmab plans to engage global regulatory authorities and submit full results for presentation at a future medical meeting; petosemtamab already holds FDA Breakthrough Therapy Designation for this indication and is in three additional Phase 3 trials in HNSCC and colorectal cancer.
• 4d ago AI analysis › Press Release ● Critical ⚠ 2
REG-Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab's Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab in first-line PD-L1+ recurrent/metastatic head and neck cancer met both primary endpoints at the first interim analysis.
The combination cut the risk of death by 50% (OS HR 0.50, p<0.0001) and improved ORR (odds ratio 3.17) versus pembrolizumab alone, regardless of HPV status, with no new safety signals.
Genmab plans to engage global regulatory authorities and will submit full results for presentation at a future medical meeting; it will host an investor update at 5:00 p.m. CET on October 28.
• 4d ago AI analysis › Press Release ⚠ 3
Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
Genmab's updated Phase 2 data for petosemtamab, an EGFR x LGR5 bispecific antibody, showed confirmed and unconfirmed ORRs of 75% in first-line and 67% in second-line metastatic colorectal cancer, with 81% ORR in first-line left-sided tumors.
The longer follow-up confirmed most previously unconfirmed responses, supporting Genmab's ongoing global Phase 3 development program; findings were presented at the ESMO Congress 2026.
Note this is a paid third-party promotional roundup by FN Media (compensated $4,900 tied to GT Biopharma coverage), not a Genmab-issued release, and the Genmab data are recaps of previously announced ESMO results.
• 6d ago AI analysis › Press Release ● Major ⚠ 2
Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab reported updated Phase 2 data showing petosemtamab plus pembrolizumab achieved a 28.2-month median overall survival in first-line recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma.
The combination posted a 63% ORR, 9.0-month median PFS, and 19% complete response rate (n=43), with responses across both HPV-positive and HPV-negative disease and no treatment-related deaths.
The data were presented at ESMO 2026 and compare favorably to the ~10-12 month median OS standard in r/m HNSCC, ahead of Phase 3 LiGeR-HN1 topline data anticipated later this year.
• 6d ago AI analysis › Press Release ● Major ⚠ 2
REG-Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Genmab reported updated Phase 2 data showing petosemtamab plus pembrolizumab achieved a 28.2-month median overall survival in first-line recurrent/metastatic PD-L1+ head and neck squamous cell carcinoma, roughly 2.5x the historical 10-12 month benchmark.
The efficacy-evaluable population (n=43) showed a 63% overall response rate, 19% complete response rate, and 9.0-month median PFS, with responses observed across both HPV-positive and HPV-negative disease and no treatment-related deaths.
The Phase 3 LiGeR-HN1 trial in this indication is ongoing with topline data anticipated later this year, and Genmab will host an investor update on October 28.
The data strengthen the commercial case for petosemtamab ahead of the pivotal readout; safety was manageable with common Grade 3-4 TEAEs at ~7%.
• 6d ago AI analysis › Press Release ● Major ⚠ 2
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab reported updated Phase 2 data for petosemtamab plus FOLFOX/FOLFIRI in metastatic colorectal cancer, with confirmed/unconfirmed ORRs of 75% in first-line and 67% in second-line patients.
Responses deepened with longer follow-up — ORR reached 81% in 1L left-sided tumors, disease control rates were 95% (1L) and 93% (2L), and most previously unconfirmed responses were subsequently confirmed. Safety was manageable, with discontinuations due to TEAEs in only 5% and 3% of patients.
The data reinforce the ongoing global Phase 3 LiGeR trials in mCRC and HNSCC, and Genmab will host an investor update on October 28 at 5:00 p.m. CET.
• 7d ago AI analysis › Press Release ⚠ 2
REG-Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab presented updated Phase 2 follow-up analyses of petosemtamab plus FOLFOX/FOLFIRI in metastatic colorectal cancer at the ESMO Congress 2026.
Confirmed and unconfirmed objective response rates were 75% in first-line and 67% in second-line patients, rising to 81% in 1L patients with left-sided tumors, and most previously unconfirmed responses were confirmed with longer follow-up.
Safety was manageable, with discontinuations due to petosemtamab-related TEAEs in 5% (FOLFOX) and 3% (FOLFIRI) of patients and no treatment-emergent deaths.
The data support the ongoing global Phase 3 LiGeR program in mCRC and HNSCC; Genmab will host an investor update on October 28.
• 7d ago AI analysis › Press Release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to evaluate petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 and chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer.
Genmab will conduct the Phase 1/2 study; Incyte will co-fund the trial and supply INCB161734.
The deal extends petosemtamab's development beyond its two ongoing Phase 3 trials in RAS/BRAF wild-type metastatic CRC, targeting a mutation seen in roughly 15% of colorectal cancers.
• 8d ago AI analysis › Press Release
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to test petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 with standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer.
Genmab will conduct the Phase 1/2 study, while Incyte co-funds the trial and supplies INCB161734.
For Genmab, the collaboration extends petosemtamab's development into a novel combination in an indication with high unmet need; G12D is the most common KRAS mutation in colorectal cancer, occurring in roughly 15% of CRC cases.
• 8d ago AI analysis › Press Release
REG-Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte announced a clinical trial collaboration to evaluate petosemtamab plus Incyte's KRAS G12D inhibitor INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer.
Genmab will conduct the Phase 1/2 study, while Incyte will co-fund the trial and supply INCB161734, sharing development cost and risk.
The deal expands petosemtamab's development beyond its two ongoing Phase 3 trials in RAS/BRAF wild-type mCRC into a biomarker-defined niche — KRAS G12D mutations occur in roughly 15% of colorectal cancers — an early-stage optionality event with no near-term revenue impact.
• 8d ago AI analysis › Press Release ● Critical ⚠ 2
Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Genmab's Phase 3 RAINFOL-02 trial of Rina-S in platinum-resistant ovarian cancer met its primary endpoint of progression-free survival and its key secondary endpoint of overall survival versus investigator's choice chemotherapy.
In the intent-to-treat population (N=584), Rina-S cut the risk of progression or death by 71% (HR 0.29, p<0.0001) and the risk of death by 57% (OS HR 0.43), regardless of FRα expression or prior mirvetuximab treatment, with no new safety signals.
Genmab plans to engage regulatory authorities worldwide and will submit the data for presentation at a future medical meeting; an investor update is scheduled for October 28.
• 9d ago AI analysis › Press Release ● Critical ⚠ 2
REG-Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
Genmab's Phase 3 RAINFOL-02 trial of Rina-S in platinum-resistant ovarian cancer met its primary PFS endpoint and its key secondary OS endpoint with statistical significance, showing a 71% reduction in the risk of progression or death in the intent-to-treat population (HR 0.29) and a 57% reduction in the risk of death (OS HR 0.43).
This is the first Phase 3 readout from the Rina-S program, and efficacy held regardless of FRα expression level or prior mirvetuximab treatment, positioning Rina-S for a broad patient population in a setting with poor prognosis and limited options.
Genmab plans to engage regulatory authorities worldwide and will host an investor update on October 28; four additional Phase 3 trials of Rina-S are ongoing across ovarian, endometrial, and other cancers.
• 9d ago AI analysis › Press Release
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Genmab announced worldwide net trade sales of DARZALEX totaled USD 4,239 million in the third quarter of 2026, as reported by partner Johnson & Johnson.
Sales split into USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world, including the subcutaneous DARZALEX FASPRO product.
Genmab earns royalties on all worldwide DARZALEX sales under its exclusive license to J&J, so the quarter's sales pace directly drives Genmab's royalty revenue.
• 19d ago AI analysis › Press Release
REG-Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Genmab announced worldwide DARZALEX net trade sales of $4,239 million for Q3 2026, as reported by license partner Johnson & Johnson.
U.S. sales were $2,528 million with the rest of the world at $1,711 million, including the subcutaneous DARZALEX FASPRO product.
Genmab earns royalties on all worldwide DARZALEX sales under its exclusive license to J&J, so the figure is a positive quarterly read-through for Genmab's royalty revenue.
• 19d ago AI analysis › Press Release
REG-Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Genmab A/S held its Extraordinary General Meeting, which approved the Board of Directors' 2026 remuneration proposal including share-based compensation.
A total of 5,300 restricted stock units were granted to board members at a fair value of DKK 2,487.00 per unit, vesting after three years.
This is routine governance housekeeping under the company's Remuneration Policy and carries no operational or financial signal.
• 25d ago AI analysis › Press Release ● Critical ⚠ 2
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie and Genmab announced that epcoritamab plus R-CHOP significantly improved progression-free survival versus R-CHOP alone in newly diagnosed DLBCL patients, cutting the risk of progression or death by 51% (HR 0.49, p<0.0001).
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination to show a statistically significant PFS benefit in frontline DLBCL; the IDMC recommended unblinding based on the benefit.
The companies will engage global regulatory authorities, and the combination could become a new standard of care — expanding the EPKINLY franchise into a frontline indication. AbbVie shares commercial responsibilities in the U.S. and Japan and leads further global commercialization.
• 27d ago AI analysis › Press Release ● Major ⚠ 2
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
AbbVie and Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial of epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma.
The trial met its primary endpoint, cutting the risk of disease progression or death by 51% (HR 0.49; p<0.0001) with a safety profile consistent with the individual agents.
The companies will engage global regulatory authorities on next steps; epcoritamab plus R-CHOP is not yet approved in the frontline setting, but the data could support a new standard of care and expand the EPKINLY label.
• 27d ago AI analysis › Press Release ⚠ 1
REG-Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab and AbbVie announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial, with epcoritamab plus R-CHOP demonstrating a statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients with IPI scores of 2 to 5.
The risk of disease progression or death was reduced by 51% (HR 0.49; p<0.0001), the first Phase 3 win for a bispecific antibody combination in frontline DLBCL, with a safety profile consistent with the individual agents.
The companies will engage global regulatory authorities to determine next steps; AbbVie shares U.S. and Japan commercialization of epcoritamab and holds ex-U.S./Japan global rights, making a frontline label expansion a meaningful upside for its oncology franchise.
• 27d ago AI analysis › Press Release ● Major ⚠ 3
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab reported Phase 2 RAINFOL-01 Part C results for Rina-S in platinum-resistant ovarian cancer, showing a confirmed ORR of 45.9% among 109 patients, with five complete responses and a median duration of response of 12.1 months.
Median progression-free survival was 9.5 months, the first PFS data for the program, and antitumor activity was seen regardless of FRα expression level, including in non-expressers and prior mirvetuximab recipients.
Safety was manageable, with no ocular toxicity, neuropathy, ILD, or stomitis signals, and only 5.5% discontinuation due to adverse events. Four Phase 3 RAINFOL trials across ovarian and endometrial cancer continue to advance.
• 29d ago AI analysis › Press Release ⚠ 2
REG-Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab reported Part C results from the Phase 1/2 RAINFOL-01 trial showing Rina-S achieved a 45.9% confirmed ORR and 12.1-month median duration of response in 109 patients with platinum-resistant ovarian cancer.
Median PFS was 9.5 months — the first PFS data for the program — and antitumor activity was observed regardless of FRα expression level, broadening the potential addressable population.
Safety was manageable, with 5.5% discontinuation due to adverse events and no signals for ocular toxicity, neuropathy, ILD, or stomatitis. The data support the four ongoing Phase 3 RAINFOL trials in gynecologic cancers.
• 29d ago AI analysis › Press Release
Major Shareholder Announcement
Genmab A/S disclosed that Darwin Global Management Limited controls voting rights attached to 3,188,361 shares, or 5.11% of Genmab's voting rights, as of September 28, 2026.
The notice is a routine filing under Section 30 of the Danish Capital Markets Act, triggered by Darwin crossing the 5% threshold through funds it manages via shares and ADRs.
The disclosure carries no stated change in intent or strategy and has no direct bearing on Genmab's operations or pipeline.
• 0mo ago AI analysis › Press Release
REG-Major Shareholder Announcement
Genmab disclosed that Darwin Global Management Limited controls voting rights attached to 3,188,361 Genmab shares, equal to 5.11% of voting rights, as of September 28, 2026.
The notice is a routine filing under Section 30 of the Danish Capital Markets Act following Darwin crossing the 5% disclosure threshold through funds it manages.
This is a regulatory ownership disclosure with no operational or financial impact on the company.
• 0mo ago AI analysis › Press Release
REG-Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab's Board granted 13,794 restricted stock units and 13,331 warrants to employees of the company and its subsidiaries.
Both RSUs and warrants reference a grant-date share price of DKK 2,268, with the warrant exercise price set at the same level and a Black-Scholes fair value of DKK 781.96 per warrant.
The awards vest after three years and warrants expire at the seventh anniversary of the grant date; this is routine compensation housekeeping with no material financial impact.
• 1mo ago AI analysis › Press Release ● Major
Grant of Restricted Stock Units and Warrants to Employees in Genmab
globenewswire.com • 1mo ago Press Release
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com • 1mo ago Press Release
REG-Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab A/S will increase its share capital by 28,011 shares as a result of employee warrant exercises.
The shares were subscribed at various prices ranging from DKK 1,334.50 to DKK 1,948.00, with proceeds of approximately DKK 44.3 million.
The capital increase represents about 0.04% of the company's share capital and is expected to be finalized shortly.
• 1mo ago AI analysis › Press Release ⚠ 1
REG-Notice to Convene an Extraordinary General Meeting of Genmab A/S
Genmab A/S has convened an Extraordinary General Meeting for Wednesday, October 7, 2026, at 3:00 PM CEST at the company's offices in Valby, Denmark.
The notice, including a Shareholder Letter appendix, is attached to the announcement, and supporting materials — including a video message tied to shareholder outreach and the Board remuneration proposal — are available on Genmab.com.
This is procedural governance news with no financial, pipeline, or strategic content; the Board remuneration proposal is the only substantive item signaled, and the EGM channel suggests management is seeking direct shareholder support for it.
• 1mo ago AI analysis › Press Release
Notice to Convene an Extraordinary General Meeting of Genmab A/S
globenewswire.com • 1mo ago Press Release
Genmab to Participate in Upcoming Investor Conferences
globenewswire.com • 2mo ago Press Release
REG-Genmab to Participate in Upcoming Investor Conferences
Genmab announced that members of its Executive Committee will participate in fireside chats at three upcoming investor conferences in September 2026.
The conferences include the Wells Fargo 21st Annual Healthcare Conference in Boston, the Morgan Stanley Global Healthcare Conference in New York City, and the Bank of America Global Healthcare Conference in London.
Live and archived webcasts of these presentations will be available on the company's investor relations website.
• 2mo ago AI analysis › Press Release
REG-Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab announced a capital increase of 24,592 shares resulting from the exercise of employee warrants.
The shares were subscribed in cash at prices ranging from DKK 1,334.50 to DKK 1,615.00 per share, generating total proceeds of approximately DKK 37.9 million.
This increase corresponds to about 0.04% of the company's total share capital, with the new shares expected to be listed on Nasdaq Copenhagen shortly.
• 2mo ago AI analysis › Press Release
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com • 2mo ago Press Release ● Major ⚠ 1
Genmab Announces Financial Results for the First Half of 2026
Genmab reported H1 2026 revenue of $2.05 billion, up 25% year-over-year, driven by higher royalties from DARZALEX and Kesimpta and strong sales of EPKINLY.
The company announced positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma, showing a statistically significant improvement in progression-free survival.
Management raised full-year 2026 revenue guidance to $4.33-$4.53 billion and adjusted operating profit guidance to $1.07-$1.39 billion, reflecting the strength of its core franchises.
• 2mo ago AI analysis › Press Release ● Critical
REG-Genmab Announces Financial Results for the First Half of 2026
Genmab reported positive Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, demonstrating a statistically significant improvement in progression-free survival.
First-half revenue rose 25% year-over-year to $2.05 billion, driven by higher royalties from DARZALEX and Kesimpta, as well as 48% growth in EPKINLY net sales.
The company raised its full-year 2026 revenue guidance to $4.33 billion-$4.53 billion, citing stronger-than-expected royalty revenues and product sales.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
AbbVie and partner Genmab disclosed that the Phase 3 EPCORE DLBCL-1 trial failed to meet its primary U.S. endpoint of overall survival for Epcoritamab.
The study evaluated the bispecific antibody versus chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma patients ineligible for transplant.
While Epcoritamab holds accelerated approval based on response data, this miss on overall survival poses a risk to confirmatory conversion and label expansion.
The companies stated they will submit results for publication and continue other combination studies including EPCORE DLBCL-2.
• 3mo ago AI analysis › Press Release ● Major ⚠ 1
REG-Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
AbbVie and Genmab confirmed that the Phase 3 EPCORE DLBCL-1 trial failed to meet its primary endpoint of overall survival in the US.
The study compared subcutaneous epcoritamab monotherapy to investigator's choice of chemoimmunotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma ineligible for stem cell transplant.
Epcoritamab remains approved under the FDA's accelerated approval pathway for later-line treatment, and the companies continue to evaluate the drug in other combinations and earlier lines of therapy.
• 3mo ago AI analysis › Press Release ● Major
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Genmab reported worldwide net sales of DARZALEX (daratumumab) of USD 4,207 million for the second quarter of 2026, as reported by license partner Johnson & Johnson.
Net trade sales in the U.S. reached USD 2,435 million, while sales in the rest of the world totaled USD 1,772 million.
Genmab receives royalties on the worldwide net sales of both the intravenous and subcutaneous formulations under the exclusive license with J&J.
• 3mo ago AI analysis › Press Release ● Major
REG-Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
Genmab announced that worldwide net sales of DARZALEX totaled $4,207 million in the second quarter of 2026.
Sales in the U.S. reached $2,435 million, while the rest of the world contributed $1,772 million, covering both intravenous and subcutaneous formulations.
Genmab receives royalties on worldwide net sales under the exclusive license to Johnson & Johnson.
• 3mo ago AI analysis › Press Release ● Critical
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
globenewswire.com • 3mo ago Press Release ● Major ⚠ 1
REG-Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Genmab announced that the European Commission granted marketing authorization for TEPKINLY in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, marking the first bispecific-based therapy approved in Europe for this second-line setting.
The approval is supported by Phase 3 EPCORE FL-1 trial data demonstrating a 79% reduction in the risk of disease progression or death and an overall response rate of 96% compared to standard of care.
This label expansion reinforces TEPKINLY's potential across B-cell malignancies, and the company will pursue additional international regulatory approvals with partner AbbVie.
• 3mo ago AI analysis › Press Release ● Major
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial evaluating epcoritamab plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma.
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care R-GemOx.
Data showed a 60% reduction in the risk of disease progression or death based on U.S. censoring rules, with a hazard ratio of 0.40 and a p-value of less than 0.0001.
• 4mo ago AI analysis › Press Release ● Major
REG-Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Genmab announced positive topline results from the Phase 3 EPCORE DLBCL-4 trial, showing epcoritamab plus lenalidomide significantly improved progression-free survival in relapsed/refractory diffuse large B-cell lymphoma.
The combination reduced the risk of disease progression or death by 60% (HR 0.40) compared to standard-of-care chemoimmunotherapy, with a p value of less than 0.0001.
Genmab and AbbVie plan to engage global regulatory authorities based on these results.
• 4mo ago AI analysis › Press Release
REG-Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab A/S will increase its share capital by 185 shares following the exercise of employee warrants.
The shares were subscribed in cash at DKK 1,334.50 per share, generating total proceeds of approximately DKK 0.2 million, representing less than 0.001% of the company's share capital.
The new ordinary shares carry full rights and are expected to be listed on Nasdaq Copenhagen shortly after registration with the Danish Business Authority.
• 4mo ago AI analysis › Press Release
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com • 4mo ago Press Release
Major Shareholder Announcement
Genmab A/S disclosed that Orbis Investment Management Limited holds voting rights to 3,112,476 shares as of June 12, 2026.
This stake represents 4.99% of Genmab’s share capital and voting rights, triggering a mandatory disclosure under Section 30 of the Danish Capital Markets Act.
The announcement is a routine compliance filing with no accompanying strategic or operational news.
• 4mo ago AI analysis › Press Release
REG-Major Shareholder Announcement
Genmab A/S disclosed that Orbis Investment Management Limited holds 3,112,476 shares as of June 12, 2026.
This stake represents 4.99% of Genmab’s share capital and voting rights.
The announcement is a routine regulatory filing under Section 30 of the Danish Capital Markets Act, triggered by the threshold crossing.
• 4mo ago AI analysis › Press Release ● Major
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab reported positive Phase 2 data for epcoritamab in elderly patients with newly diagnosed DLBCL, presented at the EHA 2026 Congress.
In the EPCORE DLBCL-3 monotherapy arm, 66 patients showed a 67% overall response rate and 58% complete response rate, with a median progression-free survival of 13.0 months.
In the EPCORE NHL-2 combination arm (epcoritamab plus R-mini-CHOP), 28 patients achieved a 93% overall response rate and 86% complete response rate, with 76% progression-free and 82% overall survival at two years.
The data supports Genmab's strategy to expand epcoritamab into earlier lines of therapy, potentially increasing the addressable market for the co-developed asset with AbbVie.
• 4mo ago AI analysis › Press Release ● Major
REG-Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab reported positive Phase 2 data for epcoritamab in first-line treatment of diffuse large B-cell lymphoma (DLBCL) in elderly patients.
In the EPCORE DLBCL-3 trial, epcoritamab monotherapy achieved a 67% overall response rate and 58% complete response rate in patients ineligible for anthracycline-based chemotherapy.
In the EPCORE NHL-2 trial, the combination of epcoritamab with R-mini-CHOP yielded a 93% overall response rate and 86% complete response rate, with high rates of sustained minimal residual disease negativity.
These results support Genmab's strategy to expand epcoritamab (EPKINLY) into earlier lines of therapy, potentially significantly increasing the addressable market for its approved bispecific antibody.
• 4mo ago AI analysis › Press Release ● Major
Grant of Restricted Stock Units and Warrants to Employees in Genmab
globenewswire.com • 4mo ago Press Release
Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Genmab presented positive subgroup data from the pivotal Phase 3 EPCORE FL-1 trial, showing that epcoritamab plus rituximab and lenalidomide delivers consistent efficacy across high- and low-risk follicular lymphoma patients.
Progression-free survival hazard ratios were consistently below 0.3 across all subgroups, including high-risk FLIPI 3-5 patients (HR 0.25) and POD24 patients (HR 0.22), indicating a substantial reduction in disease progression risk.
Overall response rates were significantly higher with the combination therapy, reaching 96.5% in low-risk patients and 93.0% in high-risk patients, compared to 84.8% and 72.6% for the control arm, respectively.
• 4mo ago AI analysis › Press Release
REG-Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients
Genmab presented post-hoc subgroup data from the pivotal Phase 3 EPCORE FL-1 trial at the 2026 EHA Congress, showing consistent efficacy for epcoritamab plus rituximab and lenalidomide in relapsed/refractory follicular lymphoma.
Progression-free survival hazard ratios remained below 0.3 across all risk subgroups, including high-risk FLIPI 3-5 patients (HR 0.25) and those with early progression (POD24, HR 0.22).
Overall response rates were significantly higher in the combination arm, reaching 96.5% in low-risk patients and 93.0% in high-risk patients, compared to 84.8% and 72.6% respectively for the control arm.
• 4mo ago AI analysis › Press Release
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
globenewswire.com • 5mo ago Press Release
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Genmab will present 23 abstracts at the 2026 ASCO and EHA meetings, with 20 focused on its approved bispecific antibody epcoritamab (EPKINLY).
Key data includes the full results from the Phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy to chemotherapy in relapsed/refractory large B-cell lymphoma, and data from the Phase 3 EPCORE FL-1 trial in follicular lymphoma.
The presentations also cover data for investigational assets rinatabart sesutecan (in ovarian and endometrial cancer) and petosemtamab (in NSCLC), highlighting the breadth of the late-stage pipeline.
• 5mo ago AI analysis › Press Release
REG-Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Genmab will present 23 abstracts at the ASCO and EHA 2026 meetings, with 20 focused on its approved bispecific antibody epcoritamab.
Key highlights include the first full results from the Phase 3 EPCORE DLBCL-1 trial comparing epcoritamab monotherapy to chemotherapy in relapsed/refractory large B-cell lymphoma.
Additional data covers epcoritamab in combination regimens, fixed-duration use, and earlier lines of therapy, alongside updates on late-stage assets rinatabart sesutecan and petosemtamab.
• 5mo ago AI analysis › Press Release
REG-Capital Increase in Genmab as a Result of Employee Warrant Exercise
Genmab A/S will increase its share capital by 2,346 shares following the exercise of employee warrants.
The capital raise generates approximately DKK 3.0 million in proceeds and represents only 0.004% of the company's total share capital.
The new ordinary shares will carry full dividend and voting rights and are expected to be listed on Nasdaq Copenhagen shortly.
• 5mo ago AI analysis › Press Release
Capital Increase in Genmab as a Result of Employee Warrant Exercise
globenewswire.com • 5mo ago Press Release
Major Shareholder Announcement
Orbis Investment Management Limited has disclosed a 5.08% stake in Genmab A/S, controlling 3,166,357 shares.
This announcement is made under Section 30 of the Danish Capital Markets Act, which requires disclosure of significant shareholdings.
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.
• 5mo ago AI analysis › Press Release
REG-Genmab Announces Financial Results for the First Quarter of 2026
Genmab reported Q1 2026 revenue of $896 million, up 25% year-over-year, fueled by higher royalties from DARZALEX and Kesimpta collaborations as well as EPKINLY net product sales.
The FDA approved an sBLA to remove the recommendation for 24-hour hospitalization for EPKINLY patients, a significant commercial catalyst.
Operating profit was $180 million, and the company maintained its full-year 2026 guidance while integrating Merus and investing in its late-stage pipeline.
• 5mo ago AI analysis › Press Release
Genmab A/S Share Capital Reduction
globenewswire.com • 6mo ago Press Release
Major Shareholder Announcement
globenewswire.com • 6mo ago Press Release ● Major
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
globenewswire.com • 6mo ago Press Release
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
businesswire.com • 6mo ago Press Release
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
globenewswire.com • 7mo ago Press Release
Major Shareholder Announcement
globenewswire.com • 7mo ago Press Release
Major Shareholder Announcement
globenewswire.com • 7mo ago 
